BioMarin Official Calls Drisapersen AdCom ‘Critical Thinking On Display’
Executive Summary
CMO says advisory committee was tough on proposed Duchenne muscular dystrophy treatment in part because it was first to reach that stage.
You may also be interested in...
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.